What are the indications, technique, and postoperative management for ureteroscopy in the diagnosis and treatment of ureteral strictures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ureteroscopy and Ureteral Stricture: Comprehensive Overview

Ureteroscopy as Primary Treatment Modality

Ureteroscopy (URS) has evolved into a highly effective and safe first-line treatment for ureteral stones across all ureteral locations, with overall stone-free rates of 81-94% and long-term stricture formation occurring in only 2% or less of cases 1. The procedure achieves superior outcomes with flexible ureteroscopes for proximal stones (87% success) compared to rigid instruments (77%), while rigid/semirigid scopes excel for distal stones (94% success) 1.

Key Technical Advantages

  • Complication rates: Ureteral perforation reduced to <5% with modern equipment 1
  • Stone-free rates by location:
    • Proximal ureter: 81% overall (93% for stones ≤10mm, 87% for >10mm) 1
    • Middle ureter: 86% overall (91% for ≤10mm, 78% for >10mm) 1
    • Distal ureter: 94% with rigid/semirigid scopes 1

The holmium:YAG laser and smaller caliber instruments have fundamentally transformed URS into a safer modality with reduced morbidity compared to historical approaches 1, 2.


Ureteral Stricture Following Ureteroscopy

Incidence and Risk Factors

Postoperative ureteral stricture development is uncommon (1.4% overall) but increases dramatically with specific intraoperative complications 3. The most critical risk factors include:

  • Stone impaction: 27.2% stricture rate (P=0.002) 3
  • Balloon dilation: 10.4% stricture rate (P=0.0052) 3
  • Mucosal perforation: 16.6% stricture rate (P=0.0326) 3
  • Frequent surgery and ureteral trauma: Elevated risk 4

Important caveat: Persistent postoperative pain after stent removal does NOT predict stricture formation (3.6%, P=0.139) 3.


Postoperative Imaging Strategy

Selective vs. Routine Imaging

Routine imaging after uncomplicated ureteroscopy is unnecessary; selective imaging based on intraoperative findings effectively identifies all clinically significant strictures 3. This evidence-based approach reduces unnecessary radiation exposure and healthcare costs.

Imaging Algorithm:

For COMPLICATED ureteroscopy (impacted stone, balloon dilation, perforation):

  • Ultrasound at 1-3 weeks post-stent removal to assess hydronephrosis 4, 3
  • If hydronephrosis persists or symptoms develop: CT imaging 4
  • Critical timing: 25 patients need testing to detect one persistent obstruction 4

For UNCOMPLICATED ureteroscopy:

  • No routine imaging in asymptomatic patients 3
  • Imaging only if recurrent renal colic develops 3
  • Surveillance imaging at 6-12 months for new stone growth 3

For ALL patients (symptomatic):

  • CT imaging if persistent symptoms or hydronephrosis on ultrasound 4

Temporal Pattern

Most stricture recurrence manifests within the first postoperative year 5, 6, making this the critical surveillance window.


Diagnosis of Ureteral Stricture

Clinical Presentation

Patients present with decreased urinary stream, incomplete emptying, dysuria, urinary tract infection, and rising post-void residual 7, 8, 7. However, 67.5% of post-URS strictures are detected symptomatically 6, emphasizing the importance of patient education about warning signs.

Diagnostic Workup

Initial evaluation (after history, physical, urinalysis):

  • Uroflowmetry (flow <12 mL/second suggests obstruction) 7
  • Ultrasound post-void residual 7

Definitive diagnosis requires:

  • Urethro-cystoscopy, retrograde urethrography (RUG), voiding cystourethrography (VCUG), or ultrasound urethrography 7
  • RUG with or without VCUG remains the gold standard for delineating stricture length, location, and severity 7

Critical pre-intervention assessment:

  • Determine stricture length and location before non-urgent intervention 7, 8, 7
  • Biopsy required for patients with history of carcinoma 2

Treatment of Ureteral Strictures

Endoscopic Management (First-Line)

Endoscopic treatment (balloon dilation and/or holmium laser endoureterotomy) achieves 85% success as primary therapy for benign ureteral strictures, with optimal outcomes in strictures <1cm and mild-to-moderate hydronephrosis 9, 5.

Success Rates by Stricture Characteristics:

Strictures with INTACT vascular supply:

  • Short strictures: 89.2% success with balloon dilation 10
  • Long strictures: 37.5% success with balloon dilation 10
  • Recurrent UPJ strictures: 50% success with balloon dilation 10

Strictures with COMPROMISED vascular supply:

  • Short strictures: 40% success with balloon dilation 10
  • Long strictures: 16.7% success with balloon dilation 10
  • Endoureterotomy with stenting: 89.5% success for compromised vascular supply 10

Subgroup analysis reveals:

  • Strictures <1cm: 74.4% endoscopic success 5
  • Mild-to-moderate hydronephrosis: 68.8% endoscopic success 5
  • Mean procedures required: 1.7 per patient (range 1.41-3.6) 9, 5

Surgical Reconstruction (Definitive Treatment)

Open or robotic reconstruction achieves 97.3% success compared to 60.9% for endoscopic procedures (p<0.001), representing the definitive treatment for endoscopic failures and complex strictures 5, 11.

Indications for Reconstruction:

  • Endoscopic management failure (typically after 2-4 attempts) 9, 5
  • Long strictures (>1cm), especially with compromised vascular supply 10, 5
  • Severe hydronephrosis 5
  • Complex strictures (median length 15cm in salvage cases) 12

Reconstruction Techniques:

  • Refluxing reimplantation (47.4%) 11
  • Side-to-side reimplantation (21.1%) 11
  • Ureteroureterostomy (21.1%) 11
  • Buccal mucosa graft ureteroplasty (10.5%) 11
  • Ileal ureter replacement for extensive strictures (median 25cm ileal segment) 12

Robotic approach outcomes: 94.7% surgical success at median 22.5 months follow-up 11, with major complication rates of 5.3% 11.

Salvage Options

For failed reconstruction or non-surgical candidates:

  • Indwelling ureteral stent 2
  • Nephrostomy tube 2
  • Nephrectomy for severe renal impairment (15% of stricture cases) 5

Special Considerations

Malignant Strictures

Malignant strictures respond poorly to balloon dilation alone 2. Open or laparoscopic resection indicated if curative potential exists; otherwise, indwelling stent or nephrostomy tube for palliation 2.

Endometriosis-Induced Strictures

Maintain high index of suspicion in premenopausal women with ureteral strictures 11. Only 73.6% have known preoperative endometriosis diagnosis, with 26.3% diagnosed postoperatively on pathology 11. Robotic reconstruction achieves 94.7% success 11.

Allium Stent Failures

For complex strictures after Allium stent failure (median dwelling time 12.5 months), ileal ureter replacement serves as viable salvage option 12. Reasons for stent failure include recurrent UTI, migration, unrelieved hydronephrosis, and calculus formation 12.


Prognostic Factors

Multivariate analysis identifies reconstruction as significantly superior to endoscopic procedures (HR 0.052,95% CI 0.007-0.394, p=0.004) 5. Poor prognostic indicators include:

  • Higher age-adjusted Charlson Comorbidity Index 6
  • Older age 6
  • Stricture length >1cm 5
  • Severe hydronephrosis 5

Notably, stone impaction history shows no significant association with treatment outcomes 6, though it dramatically increases stricture risk initially 3.


Follow-Up Protocol

Most stricture recurrence appears within the first postoperative year 5, 6, requiring:

  • Median follow-up of 24 months minimum 5
  • Clinical assessment for symptoms (decreased stream, incomplete emptying, dysuria, UTI) 7, 8
  • Imaging if symptomatic or high-risk features present 4, 3

Long-term surveillance (for stone disease):

  • Stone-free patients: discharge after 2 years (radiopaque) or 3 years (radiolucent) for 80% safety margin 4
  • High-risk patients on medical management: minimum 4-year follow-up 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.